In addition to immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs), the anti-CD38 antibody (Ab) daratumumab was approved for relapsed and/or refractory MM (RRMM) and has moved into the frontline setting for newly diagnosed MM (NDMM) [10–14]. Here, CD38 is linked to Miyoshi myopathy.